FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:926-927 March 26, 1998 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

Second edition, revised and expanded. Edited by Myron M. Levine, Graeme C. Woodrow, James B. Kaper, and Gary S. Cobon. 1215 pp., illustrated. New York, Marcel Dekker, 1997. $195. ISBN 0-8247-0061-9.

The past 10 years have seen an expanded scientific and commercial interest in the potential of new vaccines. Scientific advances have created new tools for developing vaccines for diseases for which no vaccines exist. The complete genomic sequence of a pathogen provides a catalogue of potential vaccine components. Improved techniques of protein purification and peptide synthesis facilitate the identification, isolation, and engineering of candidate vaccines. Novel adjuvants, formulations, and delivery systems to induce an optimal immune response have been developed. Recombinant-DNA techniques facilitate the construction of live vaccines, live vectors, or nucleic acid vaccines into which a gene coding for . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.